Petros Pharmaceuticals, Inc. (PTPI)

0.6399 0.0000 (0.00%) At close: 04:00PM EDT

Petros Pharmaceuticals, Inc.

1185 Avenue of the Americas
Suite 249
New York, NY 10036
United States
973 242 0005
https://www.petrospharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 21

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John David Shulman	Executive Chairman of the Board	N/A	N/A	1963
Mr. Fady Boctor M.B.A.	President & Chief Commercial Officer	681.97k	N/A	1978
Mr. Mitchell S. Arnold M.B.A.	VP of Finance & Chief Accounting Officer	465.68k	N/A	1964

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Corporate governance

Petros Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.